Compass Therapeutics, Inc. (CMPX) insider trading
Compass Therapeutics, Inc. insiders have made 2 open-market purchases worth $21k since Sep 25, 2026, by 1 insider. The latest: Neil Lerner (Chief Accounting Officer) bought $18k, filed Oct 2, 2026, scored 26 out of 100.
Follow CMPX, freeOpen the live feed
A free account gets an alert the minute a new buy or sale is filed.
Insider purchases
| Filed | Insider | Stake | Score | Bought | 1 week | 1 month |
|---|---|---|---|---|---|---|
| Oct 2 Form 4 (opens sec.gov) |
Neil LernerChief Accounting OfficerChief Accounting Officer · Near 52-week low · Penny stock: hard to trade | +5% stake | 26 | $18k 20,000 at $0.92 |
— | — |
| Sep 25 Form 4 (opens sec.gov) |
Neil LernerChief Accounting OfficerChief Accounting Officer · Near 52-week low · Penny stock: hard to trade | +1% stake | 22 | $3k 2,500 at $1.14 |
— | — |
Insiders who bought CMPX
- Neil Lerner Chief Accounting Officer
Questions
Are insiders buying CMPX stock?
Yes. In the last 90 days, 2 open-market purchases were filed, worth $21k.
Who bought CMPX stock most recently?
Neil Lerner, Chief Accounting Officer, bought 20,000 shares for $18k (Form 4 (opens sec.gov), filed Oct 2, 2026).
How does InsiderBeacon score an insider buy?
Out of 100, from who bought, how much their stake grew, the size of the trade, whether other insiders bought within ten days, where the price sat in its 52-week range, and whether it was a first or a routine buy. The score is fixed when the filing arrives. The formula and the research behind it.
Insiders are also buying, same industry
Data as of Oct 2, 2026, from SEC EDGAR Form 4 filings: open-market purchases (code P) of $25,000 or more, and open-market sales. Every row links to its filing. Scores summarise what a filing says (how the score works); outcomes are hypothetical, from the first close after the filing, and past results don't predict future ones. Disclaimer